Results 41 to 50 of about 8,834,434 (252)

The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report

Journal of Medical Case Reports, 2022
Background There are currently no approved medications for impaired social cognition and function, core symptoms of autism spectrum disorder. We describe marked improvement of these symptoms with long-term low-dose administration of the partial µ-opioid ...
Charlotte Skoglund, Siri Leknes, Markus Heilig   +2 more
doaj   +1 more source

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Drugs in Context, 2023
Opioid use disorder (OUD) is a serious medical condition with vast social, health and economic impact. Individuals with OUD are prescribed opioid agonist therapies, such as methadone, levomethadone, buprenorphine or naloxone/buprenorphine, to reduce the ...
Guido Mannaioni, Fabio Lugoboni
doaj   +1 more source

Innovative Approach Reveals How Receptors Control G Protein State Equilibria

Advanced Science, EarlyView.
Using conformational specific trFRET biosensors of the Gi protein (depicted at the bottom), the authors show that receptor activation can not only release GDP from the inactive G protein, but can also release GTP from the activated G protein, leading to the reformation of the RG ternary complex.
Alexandre Bouyssou, Mélanie Da Silva, Julien Soulé, Ludovic Fabre, Laurent Lamarque, Rémy Sounier, Thierry Durroux, Sébastien Granier, Thomas Roux, Elodie Dupuis, Eric Trinquet, Philippe Rondard, Jean‐Philippe Pin   +12 more
wiley   +1 more source

EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

Advanced Science, EarlyView.
Administration of opioids activates ephrinB2‐EphB1 receptor signaling. Activated EphB1 receptors induce GRK2‐mediated phosphorylation of MOR at Ser375, which initiates the internalization of MOR and reduces opioid antinociception at the behavioral level. ABSTRACT Opioids are the primary treatment for severe pain in clinical practice.
Bo Peng, Xiaqing Lin, Hongyu Yao, Cheng Li, Huabao Liao, Yuexin Liu, Boxu Cao, Xue‑Jun Song   +7 more
wiley   +1 more source

Changes and trends in medication-assisted treatment in Israel

Israel Journal of Health Policy Research, 2023
Background As opioid prescription in Israel is increasing, there is a growing need for monitoring opioid use disorder and providing opioid agonist therapy.
Adi Marom, Iris Levy, Paola Rosca
doaj   +1 more source

Paediatric clonidine medication errors: Findings from a multicentre French study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard, Anthony Facile, Marion Lepelley, Morgane Cellier, Laurent Chouchana, Sophie Gautier, Ramy Azzouz, Thierry Vial, Annie‐Pierre Jonville‐Bera   +8 more
wiley   +1 more source

Substances used and OAT (Opioid agonist therapy).

, 2022
Substances used and OAT (Opioid agonist therapy).
Mitchell Levine (445928), Sarah van Gaalen (12436936), Dale Kalina (12436933), Aidan Reid Findlater (12436939), Mark Loeb (248712), Elizabeth Alvarez (4908070), Marek Smieja (117473), Sureka Pavalagantharajah (12436924), Anna Cvetkovic (10670541), Jacqueline Lim (4238824), Eric Lentz (12436930), Lawrence Mbuagbaw (117465), Carol Bassim (12436942), Cynthia Lokker (3813832), Jean-Eric Tarride (201689), Tim O’Shea (8283081), Chris P Verschoor (12436927), Robin Lennox (8314125)   +17 more
core   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Acute toxic leucoencephalopathy following protonitazene ingestion

British Journal of Clinical Pharmacology, EarlyView.
Background Distribution of illicit counterfeit alprazolam containing the highly potent synthetic opioid‐receptor agonist protonitazene recently resulted in a number of severe overdoses in Ireland. We report three cases that presented to our hospital, within 6 weeks of one another, following ingestion of illicitly‐sourced alprazolam.
Ruadhan O'Laoi, Holly Acton, Pierce Kavanagh, Isabelle Hunt, Niall Sheehy, Cormac Kennedy   +5 more
wiley   +1 more source

Rocavorexant, a novel, selective orexin‐1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Rocavorexant (INDV‐2000), a selective orexin‐1 receptor antagonist, reduces drug self‐administration and anxiety in nonclinical studies. This Phase 1 programme evaluated the safety, pharmacokinetics and pharmacodynamics of rocavorexant in healthy volunteers and treatment‐seeking individuals with opioid use disorder (OUD).
Martin Kankam, Rana Al‐Awam, Rajinder Shiwach, Andrew S. Huhn, Malcolm A. Young, Robert L. Dobbins   +5 more
wiley   +1 more source